IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Core Insights - IMUNON, Inc. is in Phase 3 development of its DNA-mediated immunotherapy, IMNN-001, targeting advanced ovarian cancer, showcasing significant potential as highlighted in a recent public webcast featuring key opinion leaders and clinical data [1][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [3] - The company is advancing its non-viral DNA technology through two main modalities: TheraPlas for gene-based delivery of cytokines in solid tumors, and PlaCCine for gene delivery of viral antigens [3] Clinical Programs - The lead clinical program, IMNN-001, is a DNA-based immunotherapy for localized treatment of advanced ovarian cancer, having completed multiple trials including a Phase 2 trial (OVATION 2) and currently conducting a Phase 3 trial (OVATION 3) [4] - IMNN-001 functions by instructing the body to produce cancer-fighting molecules at the tumor site, including interleukin-12 and interferon gamma [4] - The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101, and aims to advance its technological capabilities through partnerships [4]